newsfilter
← Latest News
Earnings Call Transcripts·

TerrAscend Corp. Third Quarter 2026 Financial Results - TerrAscend Corp.

TSNDF

  • Financial Performance:

    • Third quarter 2026 revenue totaled $68.2 million, representing a 5% year-over-year increase.
    • Gross margin improved to 52.3%, up from 52.1% in the prior year quarter.
    • Adjusted EBITDA reached $17.5 million (25.6% margin), compared to $17 million in Q3 2025.
    • Net loss from continuing operations narrowed to $5.5 million, driven by a $4.8 million gain on derivative liabilities.
    • Operating cash flow was positive for the 17th consecutive quarter at $8.8 million; free cash flow was positive for the 13th consecutive quarter at $6.1 million.
    • Operating cash flow and free cash flow yields stood at 17.7% and 14%, respectively.
    • The company ended the quarter with $42.5 million in cash and no material debt maturing until 2028.
    • G&A expenses increased to $24 million (35.2% of revenue) due to one-time transaction costs and professional fees excluded from adjusted EBITDA.

  • Guidance and Future Outlook:

    • Management expects mid-single-digit year-over-year revenue growth and consistent gross margin performance for Q4 2026.
    • Long-term outlook projects a significantly transformed business model by 2027, contingent on disciplined M&A and regulatory shifts.
    • Potential upside identified from federal rescheduling of medical cannabis to Schedule 3, which would eliminate the 280E tax burden and potentially offer retroactive tax relief.
    • Anticipated growth from the December 11th enforcement of the intoxicating hemp ban, expected to drive consumers back to the regulated market.
    • Company is actively pursuing a potential uplisting to a U.S. exchange.

  • Business Segments and Product Lines:

    • New Jersey: Revenue grew slightly YoY; closed on the "Aunt Mary's" acquisition (5th dispensary), generating over $10M annualized revenue immediately accretive to EBITDA; completed capacity expansion at Boonton Cultivation Facility targeting 20% higher yield; Legend brand holds #1 market share in vapes (12.1%) and #3 in flower (8.3%).
    • Maryland: Revenue grew YoY and sequentially with gross margins in the high 50s; operating at ~$75M annualized revenue; gained market share across all categories with new launches in Valhalla, Kind 3, and Tyson 2.0 edibles.
    • Pennsylvania: Strongest performing market with 16.8% total revenue growth (12% same-store sales growth, 31% wholesale growth) and 800 basis points of gross margin expansion; facility operating at near 50% capacity with significant upside for medical and adult use demand.
    • Ohio: Double-digit sales growth as consumers return to regulated channels following the hemp ban; strategy focuses on building a scaled retail footprint via accretive acquisitions.
    • Product Innovation: Significant launches across markets including 100mg medical trochies, expanded Valhalla edibles, and Q1 brands; infusion of new products driven by demand for solventless and premium items.

  • Market and Competitive Landscape:

    • Pennsylvania and Maryland markets saw the company gain market share across all categories; price compression noted in New Jersey but managed through brand strength.
    • The intoxicating hemp market is identified as the industry's largest competitor; expected to shrink, transferring volume to licensed operators.
    • Company differentiates via vertical integration, high product freshness (under 60 days), and a dual-brand strategy (premium and value) that drives consumer loyalty and price stability even as state averages decline.
    • In New Jersey, the company maintained same-store volume growth despite new competition opening near flagship locations.

  • Risks and Challenges:

    • Federal regulatory timelines and outcomes remain uncertain, specifically regarding DEA on-site inspections and final rescheduling.
    • M&A execution risk; management noted a recent "miss" on a Pennsylvania multi-store stalking horse bid due to price discipline.
    • Potential for distressed asset acquisitions in new or core markets requires careful valuation to ensure accretion.
    • Market volatility and competition remain factors, though the company emphasizes its defensive margins and brand loyalty.

  • Management Commentary and Tone:

    • Tone was confident and disciplined, emphasizing profitability and cash flow over pure top-line scale ("focused on being the best, not the biggest").
    • Management expressed high confidence in the company's ability to create long-term value and cited strong fundamentals as a basis for future growth.
    • Executives emphasized operational efficiency, with Pennsylvania described as having a "magic bullet" of growth driven by consumer preference for fresh, high-quality products.
    • Reiteration of capital allocation priorities: disciplined M&A, share repurchases (1.013M shares repurchased this quarter), and organic growth.

  • Analyst Questions and Answers:

    • Pennsylvania Growth Drivers: Clarified that the 16.8% growth comprises 12% same-store retail sales and 31% wholesale revenue, driven by brand portfolio strength, marketing, and fresh supply.
    • Pennsylvania Capacity: Facility is at ~50% capacity with no immediate CapEx needed; prepared for adult use implementation and organic demand increases.
    • M&A Strategy: While they missed one specific Pennsylvania deal due to price discipline, they remain active in PA, Ohio, and new states (FL, MO), looking for deals that are immediately accretive to EBITDA and cash flow.
    • New Jersey Cadence: New store openings are having minimal negative impact on same-store sales due to targeted pricing and brand loyalty; wholesale benefits from broader distribution.
    • Hemp Ban Impact: Ohio data shows 20-30% revenue lifts for operators seeing consumers exit synthetic markets; company views this as a multi-year tailwind to double industry size.

  • Other Key Points:

    • The "Aunt Mary's" acquisition in New Jersey closed in late September, contributing marginally to Q3 revenue but immediately accreting to EBITDA.
    • Share repurchase program renewed for up to $10 million or 10 million shares for the period August 2026–August 2027.
    • Company maintains a "cultivation-forward" model to ensure supply for retail and wholesale verticality.
    • Management reiterated that reported results include the impact of the 280E tax, which is expected to be eliminated upon medical rescheduling, materially improving future profitability.